Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

728 - Association of immune-related pneumonitis with the phenotypic appearance of concurrent ILD in patients treated with anti-PD-1 antibody

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Ryota Shibaki

Citation

Annals of Oncology (2018) 29 (suppl_9): ix150-ix169. 10.1093/annonc/mdy425

Authors

R. Shibaki1, S. Murakami2, Y. Matsumoto2, Y. Goto2, S. Kanda2, H. Horinouchi2, Y. Fujiwara2, N. Yamamoto2, Y. Ohe3

Author affiliations

  • 1 Department Of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan, 1040045 - Tokyo/JP
  • 2 Department Of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan, 104-0045 - Tokyo/JP
  • 3 Department Of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan, Tokyo/JP
More

Resources

Abstract 728

Background

Concurrent ILD is a risk factor for anti-tumor drug-related pneumonitis. The performance of a risk assessment for concurrent ILD prior to anti-PD-1 antibody (Ab) treatment is important for preventing immune-related (ir) pneumonitis, although this precaution is not well known.

Methods

NSCLC patients treated with anti-PD-1 Ab between December 2015 and May 2018 were retrospectively reviewed. The CT appearance of concurrent ILD was classified as either non-ILD, inconsistent with UIP, or UIP/possible UIP. The CT appearance of ir-pneumonitis was classified as having a cryptogenic organizing pneumonia-like (COP) pattern, a ground glass opacities (GGO) pattern, an interstitial pattern, a hypersensitivity (HP) pattern, or a pneumonitis not otherwise specified (Not-specified) pattern. The aim of this study was to evaluate the dependency of concurrent ILD for the development of ir-pneumonitis and the association between the CT appearance of concurrent ILD and that of ir-pneumonitis.

Results

As of the data cutoff on July 1, 2018, a total of 332 patients were included in this study. No difference in PFS was seen between ILD and non-ILD patients (median, 4.4 vs. 2.7 months, P = 0.14). The overall incidence of ir-pneumonitis was 11.4% (38/332 patients). The incidence of ir-pneumonitis was higher in patients with concurrent ILD than in those with non-ILD (35.1% vs. 8.5%, P < 0.0001). The distributions of CT appearances were as follows: for the non-ILD group,: 56.0% COP, 20.0% GGO, 4.0% interstitial, 16.0% HP, and 4.0% Not-specified; for the inconsistent with UIP group,: 57.1% COP, 42.9% GGO, 0.0% interstitial, 0.0% HP, and 0.0% Not-specified; for the UIP/possible UIP group,: 0.0% COP, 16.7% GGO, 83.3% interstitial, 0.0% HP, and 0.0% Not-specified.

Conclusions

Concurrent ILD is a risk factor for ir-pneumonitis, but anti-PD-1 Ab has a similar efficacy in concurrent ILD patients and non-ILD patients. The CT appearances of ir-pneumonitis differ among concurrent ILD groups, with non-ILD and inconsistent groups exhibiting COP and GGO patterns and the possible UIP/UIP group exhibiting a mainly interstitial pattern. Careful monitoring of patients, especially those with a UIP/possible UIP pattern on pretreatment CT, is needed.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

Y. Goto: Consulting roles: Boehringer Ingelheim; Speakers’ bureaus: Taiho, Boehringer Ingelheim, Ono, Bristol-Myers Squibb, MSD; Research Funding Taiho, Bristol-Myers Squibb, Ono. S. Kanda: Research Funding Ono Pharmaceutical; Honoraria: Ono Pharmaceutical, Bristol-Myers Squibb. H. Horinouchi: Research Funding MSD, Bristol-Myers Squibb, Ono Pharmaceutical,Taiho Pharmaceutical. Y. Fujiwara: Research Funding MSD, Bristol-Myers Squibb; Speakers’ bureaus: MSD, Taiho Pharmaceutical, Bristol-Myers Squibb, Ono Pharmaceutical. N. Yamamoto: Research Funding Taiho Pharmaceutical, Bristol-Myers Squibb, Ono Pharmaceutical; Speakers’ bureaus: Bristol-Myers Squibb, Ono Pharmaceutical. Y. Ohe: Research Funding Taiho Pharmaceutical, MSD; Honoraria: Taiho Pharmaceutical, MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.